SCHEMBL19923478

SCHEMBL19923478

CCC1C(=O)N([Si](CC)(CC)CC)C(=O)N1c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CES2 O00748 3/20 0.38
PLK1 P53350 1/20 0.37
PLK2 Q9NYY3 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 2/20 0.34
RECQL P46063 1/20 0.34
LOX P28300 1/20 0.33
LOXL3 P58215 1/20 0.33
LOXL4 Q96JB6 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
ALOX5 P09917 1/20 0.33
ELANE P08246 2/20 0.33
ALDH1A1 P00352 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19923651 0.90 CYP1A2 (0.41) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPSR1
SCHEMBL19923626 0.86 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPSR1
SCHEMBL19923608 0.84 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPSR1
SCHEMBL19923535 0.83 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPSR1
SCHEMBL19923545 0.81 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPSR1
SCHEMBL19923582 0.78 ELANE (0.43) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPSR1
SCHEMBL19923710 0.77 EHMT2 (0.47) NPSR1MEN1KMT2AELANEMAPT
SCHEMBL19923411 0.73 CYP1A2 (0.42) CYP1A2CYP2C9CYP2C19SMN1; SMN2NPSR1
SCHEMBL19923442 0.72
SCHEMBL19923764 0.72 ADRA2C (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10899718-B2 Polymers functionalized with N-protected hydantoin compounds BRIDGESTONE CORPORATION (JP) 2021-01-26 US claimed
US-20180065935-A1 POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS BRIDGESTONE CORPORATION (JP) 2018-03-08 US claimed
US-10899718-B2 Polymers functionalized with N-protected hydantoin compounds BRIDGESTONE CORPORATION (JP) 2021-01-26 US disclosed
US-20180065935-A1 POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS BRIDGESTONE CORPORATION (JP) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065935-A1 POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS PARG, HNMT, PARN CYP1A2 1941/4885CYP2C9 1621/4885CYP2C19 1347/4885
US-10899718-B2 Polymers functionalized with N-protected hydantoin compounds HNMT, PARG, PAM CYP1A2 1882/4885CYP2C9 1537/4885CYP2C19 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.